Neumora Therapeutics Inc. (NASDAQ: NMRA)’s stock price has plunge by -14.86relation to previous closing price of 16.49. Nevertheless, the company has seen a -10.00% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-08-14 that Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Is It Worth Investing in Neumora Therapeutics Inc. (NASDAQ: NMRA) Right Now?
Additionally, the 36-month beta value for NMRA is 3.80. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NMRA is 54.91M and currently, short sellers hold a 17.63% ratio of that float. The average trading volume of NMRA on October 21, 2024 was 798.21K shares.
NMRA’s Market Performance
NMRA’s stock has seen a -10.00% decrease for the week, with a 8.67% rise in the past month and a 17.59% gain in the past quarter. The volatility ratio for the week is 5.86%, and the volatility levels for the past 30 days are at 6.79% for Neumora Therapeutics Inc. The simple moving average for the past 20 days is -3.35% for NMRA’s stock, with a 9.61% simple moving average for the past 200 days.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with H.C. Wainwright repeating the rating for NMRA by listing it as a “Buy.” The predicted price for NMRA in the upcoming period, according to H.C. Wainwright is $30 based on the research report published on October 01, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $23. The rating they have provided for NMRA stocks is “Buy” according to the report published on July 22nd, 2024.
Mizuho gave a rating of “Outperform” to NMRA, setting the target price at $20 in the report published on July 08th of the current year.
NMRA Trading at 9.86% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.14% of loss for the given period.
Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 5.86%, as shares surge +10.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.71% upper at present.
During the last 5 trading sessions, NMRA fell by -9.26%, which changed the moving average for the period of 200-days by -13.64% in comparison to the 20-day moving average, which settled at $14.53. In addition, Neumora Therapeutics Inc. saw -17.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Fust Matthew K, who sale 14,049 shares at the price of $17.03 back on Oct 18 ’24. After this action, Fust Matthew K now owns 20,100 shares of Neumora Therapeutics Inc., valued at $239,319 using the latest closing price.
Fust Matthew K, the Director of Neumora Therapeutics Inc., sale 7,739 shares at $17.01 during a trade that took place back on Oct 17 ’24, which means that Fust Matthew K is holding 20,100 shares at $131,643 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.77. Equity return is now at value -77.08, with -71.73 for asset returns.
Based on Neumora Therapeutics Inc. (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -54.98.
Currently, EBITDA for the company is -187.53 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.22.
Conclusion
In conclusion, Neumora Therapeutics Inc. (NMRA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
